```html

Zollinger‑Ellison Disease (Familial)

Overview

Zollinger‑Ellison disease (ZED) is a rare, inherited form of gastrinoma—a tumor that secretes excessive amounts of gastrin, a hormone that stimulates stomach acid production. The chronic over‑production of gastric acid leads to severe peptic ulcer disease, gastro‑esophageal reflux, and a host of gastrointestinal complications.

When ZED occurs as part of an inherited syndrome, it is most often linked to multiple endocrine neoplasia type 1 (MEN 1) or, less commonly, MEN 2. These hereditary conditions are passed down in an autosomal‑dominant pattern, meaning a child has a 50 % chance of inheriting the mutation if one parent carries it.

• Prevalence: Sporadic gastrinomas affect about 1–2 per million people worldwide. Familial cases (MEN‑1‑associated) represent roughly 20–30 % of all gastrinomas.<sup>[1] Mayo Clinic</sup>
• Typical age of onset: 30–50 years for familial disease, but cases have been reported in teenagers.
• Gender: No strong sex predilection; both men and women are affected equally.

Symptoms

Because excess acid damages the lining of the gastrointestinal (GI) tract, symptoms can be extensive and sometimes mimic other conditions. The list below includes both classic and more subtle manifestations:

Gastrointestinal Symptoms

• Recurrent peptic ulcers – often multiple, deeper, or located in unusual sites (duodenum, jejunum, or even the distal small intestine).
• Abdominal pain – cramping or burning pain that may worsen after meals.
• Diarrhea – frequent, watery stools caused by acid inactivating pancreatic enzymes.
• Steatorrhea – fatty, foul‑smelling stools when fat malabsorption occurs.
• Vomiting – may contain blood (hematemesis) if ulcer erodes into a vessel.
• Gastro‑esophageal reflux disease (GERD) – heartburn unresponsive to standard therapy.

Systemic Symptoms

• Weight loss – from malabsorption and chronic pain.
• Fatigue – secondary to anemia, nutrient deficiencies, or chronic disease.
• Iron‑deficiency anemia – due to chronic GI bleeding.
• Osteopenia/Osteoporosis – long‑standing acid excess can impair calcium absorption.

Signs Specific to MEN‑1 Association

• Hyperparathyroidism (high calcium levels, kidney stones).
• Pituitary adenomas – headaches, vision changes, or hormone over‑production (e.g., prolactin).

Causes and Risk Factors

Familial ZED is **genetically driven**. The principal mechanisms are:

Genetic Mutations

• MEN1 gene mutation – encodes the tumor suppressor protein menin. Loss of function leads to uncontrolled cell growth in the pancreas, parathyroid, and pituitary glands.<sup>[2] NIH</sup>
• Other rare mutations – CDKN1B (MEN‑4) and sporadic somatic mutations in the gastrinoma tissue.

Risk Factors

• Family history of MEN‑1 or documented MEN1 mutation.
• First‑degree relatives with gastrinomas or other endocrine tumors.
• Carrying a germline MEN1 mutation even before symptoms appear (penetrance >95 % by age 50).<sup>[3] WHO</sup>

Diagnosis

Timely diagnosis hinges on a combination of clinical suspicion, laboratory testing, and imaging. The work‑up usually proceeds as follows:

1. Laboratory Evaluation

• Fasting serum gastrin level – values > 1000 pg/mL (or > 10 × upper limit of normal) are highly suggestive, especially when accompanied by low gastric pH (< 2).<sup>[4] Cleveland Clinic</sup>
• Secretin stimulation test – paradoxical rise in gastrin after IV secretin confirms gastrinoma (increase > 120 pg/mL).
• Basic metabolic panel to assess calcium, phosphate, and renal function (important for MEN‑1 evaluation).

2. Imaging Studies

• Endoscopic ultrasound (EUS) – highly sensitive for small pancreatic or duodenal tumors.
• Multiphasic contrast‑enhanced CT or MRI – delineates tumor size, location, and metastasis.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – detects gastrinomas expressing somatostatin receptors, especially useful for occult or metastatic disease.

3. Genetic Testing

If a gastrinoma is confirmed or there is a strong family history, testing for MEN1 (and, less commonly, CDKN1B) mutations is recommended. Results guide surveillance for other endocrine tumors.

4. Endoscopic Evaluation

Upper endoscopy (EGD) identifies ulcer disease, assesses for bleeding, and enables biopsy of suspicious mucosal lesions.

Treatment Options

Treatment aims to **control acid hypersecretion**, **remove or control the tumor**, and **manage associated endocrine abnormalities**.

Medical Management of Acid Hypersecretion

• Proton pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses may be 2–4 times the standard regimen, titrated to symptom control and gastric pH > 4.
• H2‑receptor antagonists – used adjunctively if PPIs are insufficient.
• Regular monitoring of serum magnesium, calcium, and vitamin B12, because chronic PPI use can cause deficiencies.

Surgical Options

• Localized tumor resection – enucleation or pancreaticoduodenectomy for solitary gastrinomas; curative in ~ 60 % of sporadic cases.
• Debulking surgery – when metastases are present, removing > 90 % of tumor burden can reduce gastrin levels and improve symptoms.
• Radiofrequency ablation (RFA) or hepatic artery embolization – for liver metastases not amenable to resection.

Systemic Therapies (for unresectable or metastatic disease)

• Somatostatin analogues (octreotide or lanreotide) – suppress gastrin secretion and may shrink tumor size.
• Targeted therapy – everolimus (mTOR inhibitor) shown to prolong progression‑free survival in neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive cells.

Management of MEN‑1 Associated Tumors

• Parathyroidectomy for hyperparathyroidism.
• Transsphenoidal surgery or medical therapy for pituitary adenomas (dopamine agonists, surgery, radiotherapy as indicated).

Lifestyle & Supportive Measures

• Small, frequent meals; avoid large fatty meals that exacerbate acid load.
• Limit caffeine, alcohol, and nicotine – all stimulate acid secretion.
• Maintain adequate hydration; consider oral rehydration solutions if diarrhea is severe.
• Calcium and vitamin D supplementation under physician guidance.

Living with Zollinger‑Ellison Disease (Familial)

Long‑term management requires a partnership between the patient, gastroenterologist, endocrinologist, and surgeon. Practical tips:

• Medication adherence – never skip PPI doses; watch for “rebound” acid hypersecretion if a dose is missed.
• Regular monitoring – check fasting gastrin levels and endoscopic surveillance every 1–2 years, or sooner if symptoms change.
• Genetic counseling – essential for affected individuals and their relatives; informs family planning and screening strategies.
• Nutrition – work with a dietitian experienced in high‑acid conditions to ensure sufficient caloric intake and prevent malnutrition.
• Psychosocial support – chronic disease can cause anxiety or depression; consider support groups or counseling.
• Vaccinations – patients on long‑term PPIs or immunosuppressive therapies (e.g., everolimus) should stay up‑to‑date on pneumococcal, influenza, and COVID‑19 vaccines.

Prevention

Because familial ZED is genetically predetermined, **primary prevention is not possible**. However, secondary prevention—reducing disease burden—focuses on early detection and lifestyle measures:

• Enroll at‑risk family members in a screening program (annual fasting gastrin, calcium, and imaging as recommended).
• Adopt a diet low in irritants (spicy foods, caffeine, alcohol).
• Avoid non‑steroidal anti‑inflammatory drugs (NSAIDs) unless prescribed, as they can worsen ulcer disease.
• Stop smoking; nicotine compounds acid secretion and impairs ulcer healing.
• Maintain a healthy weight to reduce intra‑abdominal pressure that can exacerbate reflux.

Complications

If left untreated or inadequately controlled, Zollinger‑Ellison disease can lead to serious health problems:

• Refractory peptic ulcer disease – risk of perforation, hemorrhage, and need for emergency surgery.
• Gastrointestinal bleeding – chronic blood loss causing iron‑deficiency anemia.
• Malabsorption syndromes – fat‑soluble vitamin deficiencies (A, D, E, K) and weight loss.
• Gastric outlet obstruction – swelling or scarring that blocks gastric emptying.
• Metastatic neuroendocrine tumor spread – liver, lymph nodes, or bone metastases, which worsen prognosis.
• Secondary osteoporosis – due to chronic acid exposure and possible PPI‑related calcium malabsorption.
• MEN‑1 associated cancers – parathyroid carcinoma (rare), pituitary macroadenomas, and bronchial carcinoids.

When to Seek Emergency Care

References

1. Mayo Clinic. “Zollinger‑Ellison syndrome.” Accessed May 2026. https://www.mayoclinic.org
2. National Institutes of Health (NIH). “Multiple Endocrine Neoplasia Type 1.” Genetics Home Reference. 2025. https://ghr.nlm.nih.gov
3. World Health Organization (WHO). “Classification of endocrine tumors.” 2024. https://www.who.int
4. Cleveland Clinic. “Zollinger‑Ellison Syndrome: Diagnosis and Treatment.” 2025. https://my.clevelandclinic.org
5. American College of Gastroenterology. “Guidelines for the Management of Peptic Ulcer Disease.” 2023. https://gi.org

```